Project Description:
Title: STRIDE (REN001-201): A double-blind, placebo-controlled study to evaluate the efficacy and safety of 24 weeks treatment with REN001 in patients with primary mitochondrial myopathy
Role: Site PI
Funding: Reneo Pharmaceuticals
April 2021-present
Summary: This is a randomized, double-blind, placebo-controlled, parallel group, multi-center, study designed to investigate the efficacy and safety of REN001 administered once daily over a 24-week period to patients with primary mitochondrial myopathy.